Retatrutide Lyophilised Peptide
Retatrutide is a synthetic 39-residue lipidated peptide that acts as an agonist at the GIP, GLP-1 and glucagon receptors. It has been studied in phase 1 to phase 3 clinical trials and in preclinical models. Retatrutide is supplied as a lyophilised (freeze-dried) powder in a sealed vial, in 10 mg, 20 mg and 30 mg sizes, priced RM 135–310. No certificate of analysis has been published for the batch on sale yet, so no purity figure is claimed on this page. Ships within 2 working days of payment. Sold for laboratory research use only, not for human or veterinary use.
Research use only. Sold for laboratory research only. Not for human or veterinary use, not for consumption, and not a medicine, food or cosmetic.
- Ships within 2 working days of payment.
- Free shipping across Malaysia.
- Pay by FPX online banking.
Certificates of analysis
No certificate of analysis has been published for the batch on sale yet, so this page makes no purity claim. Each certificate will name the testing laboratory, the batch, the test date and the method.
Retatrutide specifications
| Also known as | LY3437943, LY-3437943 |
|---|---|
| Form | Lyophilised (freeze-dried) powder in a sealed vial |
| Sizes | 10 mg · 20 mg · 30 mg |
| CAS number | 2381089-83-2 |
| Molecular formula | C221H342N46O68 |
| Molecular weight | 4,731.4 g/mol |
| Sequence | Tyr-Aib-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-(α-methyl-Leu)-Leu-Asp-Lys-Lys(γGlu-AEEA-C20 diacid)-Ala-Gln-Aib-Ala-Phe-Ile-Glu-Tyr-Leu-Leu-Glu-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2 (39 residues; Aib = 2-aminoisobutyric acid) |
| PubChem | CID 171390338 |
| Storage (sealed) | -20 °C (supplier specification; stability stated as ≥4 years) |
| Storage (reconstituted) | aqueous solutions not recommended for storage beyond one day (supplier insert) |
What research says about Retatrutide
Retatrutide is a synthetic 39-residue lipidated peptide that acts as an agonist at the GIP, GLP-1 and glucagon receptors. It has been studied in phase 1 to phase 3 clinical trials and in preclinical models.
Reported as a single-peptide agonist of the GIP, GLP-1 and glucagon receptors; in obese mice the glucagon receptor component was associated with increased energy expenditure alongside GIP/GLP-1 receptor-driven reduction in calorie intake (Coskun 2022).
Investigational: phase 3 TRIUMPH-1 (NEJM, Sept 2026) and TRIUMPH-2 (Lancet, 2026) results are published and no marketing authorisation was identified.
Cited studies
-
Described in vitro receptor activity, effects in obese mice, and a phase 1 single-ascending-dose study with a pharmacokinetic profile supporting once-weekly dosing.
LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept.. Cell Metabolism, 2022. doi:10.1016/j.cmet.2022.07.013 · PubMed 35985340
-
In a 48-week phase 2 trial in 338 adults, mean body-weight change was -24.2% at 12 mg versus -2.1% with placebo; adverse events were mostly gastrointestinal and dose-related.
Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.. New England Journal of Medicine, 2023. doi:10.1056/NEJMoa2301972 · PubMed 37366315
-
A phase 2 trial in adults with type 2 diabetes compared retatrutide, placebo and dulaglutide, with change in HbA1c at 24 weeks as the primary endpoint.
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA.. The Lancet, 2023. doi:10.1016/S0140-6736(23)01053-X · PubMed 37385280
-
In a 98-participant substudy, mean relative liver-fat change at 24 weeks was -82.4% at 12 mg versus +0.3% with placebo.
Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial.. Nature Medicine, 2024. doi:10.1038/s41591-024-03018-2 · PubMed 38858523
-
In the 80-week phase 3 TRIUMPH-1 trial (2,339 adults), mean body-weight change was -25.0% at 12 mg versus -3.9% with placebo; gastrointestinal events were most common.
Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity.. New England Journal of Medicine, 2026. doi:10.1056/NEJMoa2604169 · PubMed 42814954
Handling and storage
- Sealed vial
- -20 °C (supplier specification; stability stated as ≥4 years)
- After reconstitution
- aqueous solutions not recommended for storage beyond one day (supplier insert)
Shipping, returns and payment
Dispatch. Ships within 2 working days of payment.
Shipping. Free shipping across Malaysia. Peninsular Malaysia 1–4 working days; Sabah, Sarawak and Labuan 3–7 working days.
Returns. No change-of-mind returns; a wrong or damaged item is replaced or refunded. Nothing here affects your rights under the Consumer Protection Act 1999.
Payment. FPX online banking.
Questions
- Is there a certificate of analysis for Retatrutide?
Not yet for the batch on sale. When one is published it appears in the certificates table on this page with the laboratory, batch, test date, method and result. See how to read a certificate of analysis.
- How is Retatrutide stored?
Sealed: -20 °C (supplier specification; stability stated as ≥4 years). After reconstitution: aqueous solutions not recommended for storage beyond one day (supplier insert). These are supplier figures, cited in the handling section.
More about Retatrutide
-
Research summary
Retatrutide: what the published trials report
Retatrutide is a single peptide that acts at three receptors: GIP, GLP-1 and glucagon. It has been tested in phase 1, phase 2 and phase 3 trials, and the results below are what those papers report.
-
Comparison
Retatrutide vs tirzepatide: how they differ
Tirzepatide acts at two receptors, GIP and GLP-1; retatrutide adds a third, glucagon. Tirzepatide is an approved medicine in the United States, while retatrutide was still investigational when this was written.
